Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP1570 Monotherapy and Combination Therapy in Advanced Solid Tumors
NCT05083481Phase 1Terminated
- Sponsor
- Astellas Pharma
- Start
- Oct 2021
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label trial of ASP1570 in solid tumor (11 arms), sponsored by Astellas Pharma. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events up to 27 months and 3 more. Started Oct 2021; status: terminated.
02
Drugs
ASP1570
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05083481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05083481.